Symptoms

Want to keep up-to-date?

Sign up to our newsletter to get the latest Gaucher related news.

Visceral

Visceral symptoms associated with Gaucher Disease

Hematological

Hematological symptoms associated with Gaucher Disease

Skeletal

Skeletal symptoms associated with Gaucher Disease

Neurological

Neurological symptoms associated with Gaucher Disease

Symptoms

Clinical presentation of Gaucher disease is highly variable and heterogeneous. Lipid-filled Gaucher cells displace normal cells in affected organs, including the spleen, liver, bones, bone marrow, occasionally the brain and nervous system, and, in rare cases, the lungs.4-9

Accumulation of Gaucher cells can cause enlargement of the spleen and liver, and subsequently interfere with their function. In addition, Gaucher cells can cause impairment of bone marrow, anemia and thrombocytopenia, compromised bone tissue which results in fractures and pain, nervous system involvement, and in some cases rare, life-threatening pulmonary hypertension.4,7,9 In this way Gaucher disease is a multisystem disorder.

1. PASTORES, GM. et al. Semin Hematol 2004; 41(Suppl 5): 4−14.
2. INTERNATIONAL COLLABORATIVE GAUCHER GROUP (ICGG). Gaucher Registry Annual Report 2008. Available at: https://www.gauchercare.com/healthcare/registry.aspx Accessed: 12/05/16.
3. MISTRY, P. et al. Am J Hematol 2007; 82(8): 697–701.
4. MEHTA, A. Eur J Int Med. 2006;17:S2–S5.
5. PENNELLI, N et al. Blood. 1969;34:331–47.
6. GRABOWSKI, GA. Hematology Am Soc Hematol Educ Program. 2012:13–8.
7. NAGRAL, A. J Clin Exp Hepatol. 2014; 4:37–50.
8. HOPKIN, RJ and, GRABOWSKI, GA. Chapter 355. Lysosomal Storage Diseases (Chapter). Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison’s Principles of Internal Medicine.
9. KOLTER, T and SANDHOFF, K. Biochimica et Biophysica Acta.2006;1758:2057–79.
diagram_11_body
Pulmonary involvement is not generally seen at time of diagnosis; only 1-2% of patients with Type 1 Gaucher disease exhibit overt pulmonary manifestations in the form of interstitial lung disease or pulmonary vascular disease.
NB. These values represent the symptoms present at the time of diagnosis based on data from 4,936 International Collaborative Gaucher Group (ICGG) registry patients of whom 92% had type 1 disease.3 Percentages represent the proportion of patients with each symptom at diagnosis.3
*Not generally seen at time of diagnosis; only 1–2% of patients with type 1 Gaucher disease exhibit overt pulmonary manifestations in the form of interstitial lung disease or pulmonary vascular disease.
**In Gaucher disease types 2 and 3 only.

Hepatosplenomegaly

Hepatosplenomegaly (liver and spleen enlargement) occurs in nearly all symptomatic patients and may occur to a greater extent in younger patients who also have a greater degree of cytopenias.1,2 Splenomegaly is often the first clinical presentation; the spleen, which can enlarge up to 75 times, is more enlarged than the liver that can enlarge up to three times.3 Hepatosplenomegaly often leads to massive abdominal distention with anemia and thrombocytopenia.

1. MEHTA, A. Epidemiology and natural history of Gaucher’s disease. Eur J Int Med. 2006;17:S2–S5.
2. HOPKIN, RJ and, GRABOWSKI, GA. Chapter 355. Lysosomal Storage Diseases (Chapter). Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison’s Principles of Internal Medicine
3. NAGRAL A. Gaucher disease. J Clin Exp Hepatol. 2014; 4(1): 37–50.
gaucher_multi_system_disorder
Earlier Diagnosis Strategies: A Non-Haematological Perspective – Dr Jordi Pérez-López

Recent posts from Rare2Aware on Gaucher Disease

Sign up to the Gaucher newsletter

First Name (required)

Last Name (required)

Email (required)

Country (required)

Specialty (required)

With your permission, Shire would like to contact you by electronic means (such as email or SMS) with information about products and services that we feel may be of interest to you. You have the right to opt out of receiving such electronic communications, at any time, by contacting us. Depending on the country you reside in, Shire may be required by law to obtain your consent in order to be able to send such electronic communications to you.

 I consent to be contacted by Shire by electronic means with information about Shire's products and services.
We encourage you to read our privacy policy.

 I have read and accept the Terms of Use.

INTSP/C-ANPROM/GAU/16/0011d AUG2016